Form 4: Femasys Inc. Executive Granted Stock Options

Christine E. Thomas, Chief Regulatory and Clinical Officer at Femasys Inc., was granted stock options on January 28, 2025.

Summary

• Christine E. Thomas, the Chief Regulatory and Clinical Officer of Femasys Inc., received stock options on January 28, 2025.
• The stock options are for a total of 107,372 shares of common stock.
• The exercise price for all options is $1.05 per share.
• 55,090 of the options vest equally over 3 years starting January 28, 2025.
• 23,600 of the options vest equally over 4 years starting January 28, 2025.
• 28,682 of the options vest immediately on January 28, 2025.
• All vesting is contingent on continued employment with Femasys or a subsidiary.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, which is generally viewed positively as it aligns management and shareholder interests. There are no indications of negative sentiment.

Positives

• The granting of stock options aligns the executive's interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the executive.

Risks

• The value of the stock options is dependent on the future performance of Femasys' stock price.
• The executive must remain employed to fully vest the options.

Future Outlook

The stock options will vest over the next 3 to 4 years, contingent on continued employment.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology and medical device industries, aligning management's interests with shareholder value creation.

Comparison to Industry Standards

• Stock option grants are a standard practice for executive compensation in the biotech industry.
• Vesting schedules of 3-4 years are typical to incentivize long-term performance.
• The exercise price of $1.05 is specific to Femasys' stock and market conditions at the time of the grant.

Stakeholder Impact

• Shareholders may view the stock option grant positively as it incentivizes management to increase the company's value.
• Employees may see this as a positive sign of the company's commitment to its leadership.

Key Dates

Keywords

stock options, executive compensation, Femasys Inc., vesting, equity, insider trading